Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Syntara Ltd

SNT.AX ✓ COMPLIANT ☆ Track — members

ASX · Healthcare · Biotechnology & Medical Research ·

Australia Micro Cap Analyst: BUY

Last Close

$0.02

▲ +0.00%

Market Cap $36.00M · Vol 552.98K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$36.00M

Micro Cap

Div Yield

N/A

Semi-annual dividend

EPS Growth

-7.03%

YoY

RSI (14)

57.69

Momentum

Beta

0.44

vs Market

52W High

$0.03

30.44% below

52W Low

$0.01

40.72% above

Volume

552.98K

Avg 2.34M

P/B

5.38

Price-to-book

ROE

N/A

Return on equity

Free Float

72.58%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Syntara Ltd (SNT.AX) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does SNT.AX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-25.71%

+15.56%

+0.00%

-18.75%

YTD

-25.71%

-7.14%

-35.17%

-75.24%

Financials & Valuation

TTM · Annual

Total Revenue	$4.92M
Net Income	$-8,065,089.00
Revenue Growth (YoY)	+4.51%
Gross Margin	100.00%
Operating Margin	-165.70%
Net Profit Margin	-163.86%
ROE	N/A
ROA · ROIC	-77.03% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	10.41
P/B	5.38
P/FCF	N/A
EPS Growth	-7.03%
Outstanding Shares	1.96B

Technical Indicators

50-Day SMA	$0.02
200-Day SMA	$0.02
RSI (14)	57.69
Beta	0.44
52-Week High	$0.03
52-Week Low	$0.01

Volume Today	552.98K
Avg Daily Volume (30D)	2.34M
Relative Volume	0.24x
Volatility (10D)	167.71
Volatility (30D)	124.20
Free Float	72.58%

Analyst Consensus

BUY

Current Price $0.02

Mean Target $0.08

52W Low$0.01 52W High$0.03

Current

Target

$0.01 $0.03

Current Analyst target

+308.69% upside potential · 1 analysts

Identifiers

ExchangeASX

FIGIBBG001SC4TR3

ISINAU0000312480

CountryAustralia

Sub-IndustryBio Therapeutic Drugs

Earnings DateN/A

TypeStocks

Instrument TypeFULLPAID Fully Paid Ordinary

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

Syntara Limited is an Australia-based clinical-stage drug development company. The Company is targeting extracellular matrix dysfunction with its amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis. The Company’s lead candidate SNT-5505 is for the bone marrow cancer myelofibrosis which causes a build-up of scar tissue that leads to loss of red and white blood cells and platelets. The Company is also advancing topical pan-LOX inhibitors in scar revision, keloid scarring and scar prevention post-surgery. Its product candidate, SNT-4728, is an inhibitor to treat sleep disorders and slow progression of neurodegenerative diseases like Parkinson’s by reducing neuroinflammation. The Company’s other drug candidates target fibrotic and inflammatory diseases such as kidney fibrosis, NASH, pulmonary fibrosis and cardiac fibrosis.